针灸治疗结直肠癌癌症患者化疗性腹泻的有效性和安全性：一项系统综述和荟萃分析方案

摘要(中文译文)

化疗性腹泻（CID）是接受化疗治疗的癌症大肠癌患者的常见并发症。这种情况会对治疗结果产生不利影响，并可能增加死亡风险。针灸是中国传统医学的一个组成部分，在中国的临床环境中得到了广泛的应用。最近的研究结果表明，这种非药物方法可能为管理CID提供治疗优势。这值得进一步研究其临床应用。将进行一项全面的系统综述，以寻找随机对照试验（RCT），检查针灸治疗大肠癌患者CID的疗效和安全性。搜索策略包括八个主要的电子存储库：PubMed、Web of Science、Embase、Cochrane对照试验中心注册库（Central）、中国国家知识基础设施（CNKI）、万方数据、中国生物医学数据库（CBM）和中国科学期刊数据库（VIP），没有语言限制。主要终点侧重于通过两个关键参数量化的临床改善：根据肠易激综合征严重程度评分系统（IBS-SSS）分类的腹泻严重程度的改变，以及发作持续时间的改变。次要终点包括针灸相关不良反应的安全性评估，以及使用欧洲癌症研究和治疗组织生活质量问卷-核心30（EORTC QLQ-C30）对生活质量指标的综合评估。两名审评员将通过Cochrane偏倚风险工具（RoB2）独立评估所有主要结局的偏倚风险。分歧将通过讨论或第三方裁决解决。对于数据综合和荟萃分析，所有统计分析都将使用Cochrane协作网的Review Manager软件版本5.3。本系统综述将综合现有证据，评估针灸治疗结直肠癌患者CID的疗效和安全性。这些发现旨在通过评估针灸是否是循证治疗方案中可行的辅助疗法，为临床实践提供信息。普洛斯佩诺CR420251045610。

Abstract

Chemotherapy-induced diarrhea (CID) is a common complication among colorectal cancer patients receiving chemotherapeutic treatment. This condition adversely affects therapeutic outcomes and potentially increases mortality risks. Acupuncture, an integral component of traditional Chinese medicine, has gained widespread use in China's clinical settings. Recent findings suggest that this non-drug approach may provide therapeutic advantages for managing CID. This warrants further research into its clinical application. A comprehensive systematic review will be performed to find randomized controlled trials (RCTs) that examine the therapeutic effectiveness and safety of acupuncture treatments for managing CID in patients with colorectal cancer. The search strategy includes eight major electronic repositories: PubMed, Web of Science, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), China National Knowledge Infrastructure (CNKI), Wanfang Data, Chinese Biomedical Database (CBM), and China Scientific Journal Database (VIP), with no language restrictions. Primary endpoints focused on clinical improvements quantified through two key parameters: alterations in diarrhea severity according to the Irritable Bowel Syndrome Severity Scoring System (IBS-SSS) classifications, and modifications in episode duration. Secondary endpoints encompassed safety assessments of acupuncture-related adverse reactions and comprehensive evaluation of quality-of-life indicators using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). Two reviewers will independently assess the risk of bias for all primary outcomes via the Cochrane Risk of Bias tool (RoB2). Disagreements will be resolved through discussion or third-party adjudication. For data synthesis and meta-analysis, all statistical analyses will utilize Review Manager software version 5.3 from the Cochrane Collaboration. This systematic review will synthesize existing evidence to evaluate the therapeutic efficacy and safety of acupuncture in managing CID among colorectal cancer patients. The findings aim to inform clinical practice by assessing whether acupuncture represents a viable adjunctive therapy within evidence-based treatment protocols. PROSPERO CRD420251045610.

如何引用